An ever increasing hardness of drug approval processes and criteria leads to a systemic approach to novel target identification and validation. This involves a variety of methods' tools' and related data which collectively pre-validate a drug target in multiple aspects so that it can finally be approved as a new drug. Thus' a key to success of novel drug targets is to establish a target production framework in which heterogeneous methodologies work in concert with one another. Then' the problem boils down to how to make those diverse technologies function as an organic whole. Our approach in the first place is to tightly couple them together based on tangible output of those processes and methods. This requires a quantitatively standardized specification for each component because we expect that the specification can reveal the precise link point between them at a technique or data level. We are now working on the standardization of each part of our own framework such as feasibility test' mode of action' clinical validation' biomarker' assay' lead' disease model' and crystal structure. Based on the detailed specification' we will find out the common and/or compatible elements which can be used as junctions. Using these junctions' each component can be assembled into a single conglomerate and then we could landscape it for various stakeholders to intuitively share up-to-date progress status' identify bottlenecks' and resolve the problems in a cooperative and responsive manner.